Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated disease resulting from a hypersensitivity reaction to Aspergillus fumigatus. ABPA is identified by bronchial asthma, peripheral eosinophilia, high levels of serum immunoglobulin E, pulmonary infiltration, mucoid impaction, and central bronchiectasis. Diagnosing ABPA is important to consider since there are treatment options that are readily available and response to therapy yields positive results. We describe a case of ABPA present in Trinidad, West Indies, which was not described previously in the literature.

Highlights

  • Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated disease resulting from a hypersensitivity reaction to Aspergillus fumigatus [1]

  • ABPA is identified by bronchial asthma, high levels of serum immunoglobulin E (IgE), peripheral eosinophilia, pulmonary infiltration, mucoid impaction, and central bronchiectasis [1,6]

  • The International Society for Human and Animal Mycology (ISHAM) working group proposed that ABPA patients must have a predisposing factor, for example, cystic fibrosis or bronchial asthma

Read more

Summary

Introduction

Allergic bronchopulmonary aspergillosis (ABPA) is an immunologically mediated disease resulting from a hypersensitivity reaction to Aspergillus fumigatus [1]. Patients with ABPA tend to require longterm treatment with corticosteroids and in several cases antifungal agents, potentially leading to several adverse effects. Diagnoses at this time were asthma and a restrictive lung defect secondary to RML consolidation; this was thought to be due to a fungal infection, most likely Aspergillus. The HRCT showed that the consolidative changes within the middle lobe of the right lung have resolved, with only minimal atelectasis seen. Spirometry FVC (L) FEV1 (L) FEV1/FV (%) FEV6 (L) FEF25-75 [iso] (L/s) PEFR (L/s) FEF50 (L/s) FIF50 (L/s) FEF50/FIF50 MVV (L/m) Lung volumes TLC (L) VC (L) RV (L) RV/TLC (%) FRC (L) SVC (L) IC (L) ERV (L) Diffusing capacity DLCO (ml/min/mmHg) DLCO [Hb] ml/min/mmHg DLCO/VA (ml/min/mmHg) VA [BTPS] (L)

Discussion
Conclusions
Disclosures
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.